Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

DNA methylation as a biomarker in breast cancer.

Martens JW, Margossian AL, Schmitt M, Foekens J, Harbeck N.

Future Oncol. 2009 Oct;5(8):1245-56. doi: 10.2217/fon.09.89. Review.

PMID:
19852739
2.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R.

J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18.

3.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.

PMID:
17601725
4.

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW.

Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166.

5.

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.

Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA.

Cancer Res. 2005 May 15;65(10):4101-17.

6.

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.

7.

Aberrantly methylated DNA as a biomarker in breast cancer.

Kristiansen S, Jørgensen LM, Guldberg P, Sölétormos G.

Int J Biol Markers. 2013 Apr-Jun;28(2):141-50. doi: 10.5301/jbm.5000009. Epub 2013 Apr 2.

PMID:
23564623
8.

Genome-wide identification of OTP gene as a novel methylation marker of breast cancer.

Kim MS, Lee J, Oh T, Moon Y, Chang E, Seo KS, Hoehn BD, An S, Lee JH.

Oncol Rep. 2012 May;27(5):1681-8. doi: 10.3892/or.2012.1691. Epub 2012 Feb 17.

PMID:
22366991
9.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
10.

Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.

Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, Rom J, Weichenhan D, Claus R, Rehli M, Schirmacher P, Sinn HP, Plass C, Gerhauser C.

FASEB J. 2012 Dec;26(12):4937-50. doi: 10.1096/fj.12-209502. Epub 2012 Aug 28.

11.

DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.

Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A.

Diagn Mol Pathol. 2012 Jun;21(2):93-104. doi: 10.1097/PDM.0b013e318240503b.

PMID:
22555092
12.

Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA.

Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A, Ordway JM, McCombie WR, Leon J, Jeddeloh JA, McPherson JD.

Genome Res. 2008 Jan;18(1):19-29. Epub 2007 Nov 21.

13.

Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.

Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M.

Cancer Res. 2005 Feb 15;65(4):1141-5.

14.

Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C.

Cancer Prev Res (Phila). 2011 Nov;4(11):1852-62. doi: 10.1158/1940-6207.CAPR-11-0186. Epub 2011 Jul 21.

15.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

16.
17.

Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels.

Lian ZQ, Wang Q, Li WP, Zhang AQ, Wu L.

Int J Oncol. 2012 Aug;41(2):629-38. doi: 10.3892/ijo.2012.1464. Epub 2012 May 8.

PMID:
22581028
18.

DNA methylation-based biomarkers in serum of patients with breast cancer.

Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, Speeckaert M.

Mutat Res. 2012 Oct-Dec;751(2):304-25. doi: 10.1016/j.mrrev.2012.06.001. Epub 2012 Jun 12. Review.

PMID:
22698615
19.

Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.

Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, Dalay N, Santella RM.

Anticancer Res. 2010 Jul;30(7):2489-96.

20.

Strategic approach to validating methylated genes as biomarkers for breast cancer.

Wang W, Srivastava S.

Cancer Prev Res (Phila). 2010 Jan;3(1):16-24. doi: 10.1158/1940-6207.CAPR-09-0098. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk